Keep up with the latest news and press releases from the Summit.

Press Release 2022


Boston Biotechnology Summit 2022: a Virtual [Sept.] and In-Person [Oct.] program covering Medical Research and Business Issues Facing Biotechnology Companies Worldwide.
[Cambridge MA, USA, Released 19 SEPT 2022] The Boston Paris Biotechnology Summit™ 2022 will be held in two parts; virtually [29 Sept.] and in-person [14 Oct.] at CIC, the Cambridge Innovation Center, Cambridge 02142, USA.

This comprehensive program features nationally and internationally reputed speakers covering Medical Research and Business Issues Facing Biotechnology Companies: Talent Acquisition and Retention, US Legal and Regulatory Strategy, Funding & Management in Times of Crisis, a virtual Special Lecture on Monkeypox, Clinical Development and Trials – State-of-the-Art, and an in-person Master Class on Commercial strategy.

Yvette CLELAND, CEO CPL Life Sciences, London, UK. – Nominated as one of the top 50 most powerful women in staffing worldwide.

Marc DE GARIDEL, CEO Cincor Pharma, Boston MA, USA. Previously served as CEO of Corvidia Therapeutics, a private Boston-based clinical-stage company acquired by Novo Nordisk in 2020 for $2.1 Billion.

Marc B. GARNICK, M.D., Gorman Brothers Professor of Medicine at Harvard Medical School & the Beth Israel Deaconess Medical Center Boston MA, USA.

Vanessa EL HARRAR, MD, MPH, Vice President, Vaccines Business Strategy Lead at PPD [Thermo Fisher Scientific], Wilmington, NC, USA.

Naji Gehchan, MD, Global Development Leader Oncology at Eli Lilly & Co, Cambridge MA, USA.

Daniel KURITZKES, Harriet Ryan Albee Professor of Medicine at Harvard Medical School and Chief of the Division of Infectious Diseases at Brigham and Women’s Hospital, Boston, MA, USA.

Cecile LE CAMUS, MD, MBA, Global Head of Hemophilia for Rare Blood Diseases, Medical Affairs Group, Sanofi-Genzyme, Cambridge MA, USA.

Corinne LE GOFF, PharmD, MBA, CEO Celsion, NJ, USA (& Cambridge MA). Corinne Le Goff’s was listed by Forbes magazine in 2021 as “One of 100 Women Changing the World”. 

Anup MADAN, PhD, Director of Biomarkers for PPD® Laboratories, part of Thermo Fisher Scientific, Seattle, WA, USA.

Brian MALKIN, JD (Law), Partner, IP and FDA Practice McDermott Will & Emery,
Washington DC, USA.

Regis MULOT, EVP and Chief HR Officer, IPSEN, Paris, France.

Delphine SARAGOUSSI MD, MScPH, Executive Director, Real-World Evidence, Strategic & Scientific Affairs at EVIDERA (PPD, part of Thermo Fisher Scientific) Greater Paris Region, France.

Ann M. STOWE, PhD, Associate Professor with Tenure, Dept. of Neurology at the University of Kentucky (Lexington, KY, USA) & Co-founder CERELUX LLC.

Vice-President, Vaccines Strategy Lead, PPD Biotech [Thermo Fisher Group], FL, USA. Formerly, Office of the Director, NIH: National Institutes of Health, MD, USA.
Jessica FOLEY, MS, RAC
[Regulatory Affairs Certified]
Principal & Founder,
Gaia Regulatory Sciences,
Cambridge MA, USA.
Silvia HELOU, MD,
Principal & Executive Medical Consultant, Helou Consulting, LLC
New York Metropolitan Area, USA.
Professor Frederic JALLAT,
Academic Director – Biopharmaceutical Management,
ESCP Business School, Paris, France. Campus Sites: Berlin, London, Madrid, Paris, Turin & Warsaw.
Partner, IP and FDA PRACTICE,
McDermott, Will & Emery,
International Law Firm,
Washington DC, USA
Karine ROSSIGNOL, PharmD
CEO, SMART IMMUNE. Co-General Secretary, INSTITUT IMAGINE, for Rare Genetic Diseases, Paris, France.

[Major/Founding Sponsors]
PPD BIOTECH [Thermo Fisher Scientific Group], USA
CPL Life Sciences, UK.

[2022 Sponsors]
ACTIVE Biomarkers, France
BANOOK Group, France.

[Friends of the Summit]
 B2G Life Sciences, France

About the Boston Biotechnology Summit
An exclusive, Trans-Atlantic bridge designed to foster innovative synergies between biotech and pharma companies, healthcare-focused cities, regional clusters and institutional, philanthropic and strategic investors.
The Summit’s intent is to spark projects, their financing and strategic deals to solve unmet medical needs to improve patient lives globally.

All Inquiries
Soheila Gharakhanian, Summit Co-Founder & President, Blend of Concept LLC <>, Summit Producer.


Media Information 2021

Media Collaboration with the news magazine BIOTECH FINANCES


Philadelphia Business Journal

Press Release 2019

3rd edition of the Boston Biotechnology Summit™:

A Bridge for Collaboration

Cambridge MA, 30 May 2019 – The 3rd Boston Biotechnology Summit will be held on Sunday, 2 June 2019 at the renowned Wistar Institute in Philadelphia (USA), just before the BIO 2019 Convention. The central theme of this third edition will be collaboration, common foundations, research project development, obtaining regulatory approval and the marketing of products from the biotechnology industry.

Pravin Chaturvedi, PhD, 2019 Guest Program Chair, (together with Shahin Gharakhanian, MD, Co-Founder & International Program Committee Chair), who declares: “The biotechnology industry faces both opportunities and challenges in terms of technology and finance. Our success will always depend on the quality of collaborative efforts. For this reason, as Guest Program Chair, I believe in the importance of in-depth debate on this central theme at the Boston Biotechnology Summit on June 2 in Philadelphia. We are therefore inviting our colleagues to attend and participate fully in these discussions”.

Highlights of the Summit:

Biotech companies and pharmaceutical groups: Acticor, Alkermes, Bayer USA, GSK/ViiV Healthcare, Johnson & Johnson, Merck, Nanobiotix, etc.

Investors and financial platforms: AWEX, FEP Capital Advisors, Gurnet Point Capital, ($2 billion investment fund), Launchpad Ventures LLC, LSN: Life Science Nation, Nowak Ventures LLC, and groups with operations in Asia, the US and EU.

Press Release 15 May 2019

3ème édition du Boston Biotechnology Summit™ :

Un Pont pour la Collaboration

Paris (France), le 15 Mai 2019 – le « 3rd Boston Biotechnology Summit™ » se tiendra le dimanche 2 Juin 2019 au célèbre Wistar Institute à Philadelphie (Etats-Unis), juste avant la Convention BIO 2019.

La thématique centrale de cette troisième édition sera la collaboration, socle commun, des projets de recherche développement, d’approbation règlementaire et mise sur le marché de produits issus de l’industrie des biotechnologies.

Le Dr. Shahin Gharakhanian, spécialiste de Développement Clinique et de Médecine Pharmaceutique, co-fondateur et Président du Comité de Programmation annonce : «  Après les réussites du 1er Sommet de Biotechnologie Boston/Paris à l’Institut Pasteur en 2017, et la seconde édition en 2018 à l’Exchange Conference Center, lieu historique, à Boston, nous avons franchi cette année une étape stratégique par le choix et l’implication des orateurs américains et européens, mais aussi par la présence grandissante d’investisseurs asiatiques. Plus que jamais, cet événement vient compléter parfaitement l’agenda des acteurs français inscrits à BIO2019 »

Parmi les orateurs-experts présents à cette 3ème édition :

  • Sociétés de biotechnologies et groupes pharmaceutiques : Acticor, Alkermes, Bayer USA, GSK/ViiV Healthcare, Johnson & Johnson, Merck, Nanobiotix …
  • Investisseurs et plateformes financières : AWEX, FEP Captal Advisors, Gurnet Point Capital, (fond d’investissement de $2 Milliards), Launchpad Ventures LLC, LSN, Life Science Nation ainsi que des groupes ayant des opérations à Pékin, Shanghai, Bruxelles, Boston, Philadelphie et New York.
  • Institutions et Universitaires : Business France, « Forum for Collaborative Research » France Biotech, « German Accelerator Life Sciences Program », Genopole, Initiative pour les Médicaments Innovants (IMI) en Europe, The Wistar Institute, « Massachusetts Biotechnology Council », Universités d’Aix/Marseille, GSU College of Public Health, Montréal, LMU Munich.
  • Dix jeunes sociétés de biotechnologies, des « start-ups » sélectionnées, viendront présenter leur projet à un panel d’experts thérapeutiques et réglementaires, investisseurs, et industriels pharmaceutiques. Trois sociétés françaises de Lille, Paris et Marseille en font partie. 

Headlines Biotech Finances Journal

Front page, no. 813, May 2018

Press Release 30 May, 2018

Boston-Paris Biotechnology Summit®

Boston-Paris Biotechnology Summit®: Bringing Together Leaders to Bridge Business Partnerships. A Day of Learning and Meeting on New Sources of Financing and Strategic Partnerships. 

Boston, Massachusetts – 30 May, 2018 -The BOSTON-PARIS Biotechnology Summit®, an international conference that aims to foster innovation and partnerships between key trans-Atlantic stakeholders, will be hosting its second annual meeting at the Boston Exchange Center on June 3, 2018. The Summit will feature thought-leaders from biotechnology, pharmaceutical companies, city and regional bio-clusters, alongside institutional, philanthropic and strategic investors.

Press Release – March 29, 2017

BOSTON-PARIS Biotechnology Summit ® 1st Edition of the First Franco-American Exchange Event, May 18, 2017 at the Pasteur Institute, Paris 75015.

March 29, 2017:  The BOSTON-PARIS Biotechnology Summit, an international exchange conference bringing together key players from Boston and France in the biotech and investment industry, announces that it will hold its first edition in Paris on May 18, 2017, in the historic Amphitheater Duclaux of the Pasteur Institute.

Communiqué de Presse – 29 Mars 2017

Paris, France – March 29, 2017 -The BOSTON-PARIS Biotechnology Summit, an international trade conference bringing together the major Boston and French-speaking players in the biotech investment industry, is announcing that it will hold its first edition in Paris on May 18, 2017, at the Pasteur Institute’s historic Duclaux Amphitheatre.

2017 Press Coverage

  • Boursorama, Paris, Issue # 23 May 2017

  • La Bourse et La Vie, Paris, Issue # 19 April 2017

Interview with Shahin Gharakhanian,

  • Les ECHOS, Circa 2Q2017.
  • La Revenue Française, Internet Broadcast # 19 April 2017

Interview with Shahin Gharakhanian.